BioSpace takes a look at the headlines across a heavy earnings week for biotechs, checking in on Allogene, Rapport and more.

Eli Lilly announced positive results from its Phase 3b study of Ebglyss, which focused on patients with moderate-to-severe atopic dermatitis. Patients had been previously treated with Dupixent ...

Headquartered in Indianapolis, Indiana, Eli Lilly and Company (LLY) is a leading biopharmaceutical firm with a market cap of ...

We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...

Eli Lilly and Company (NYSE: LLY) announced today the U.S. Food and Drug Administration (FDA) approved EBGLYSS™ (lebrikizumab-lbkz), a targeted IL-13 inhibitor, for the treatment of adults and ...

Eli Lilly and Company (NYSE: LLY) announced today the U.S. Food and Drug Administration (FDA) approved EBGLYSS™ (lebrikizumab-lbkz), a targeted IL-13 inhibitor, for the treatment of adults and ...

One of the approvals is for Ebglyss, a treatment for atopic dermatitis that could displace the current market leader, ...

Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and ...

Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and ...

In a report released yesterday, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price target of $1,029.00. The company’s ...